InvestorsHub Logo
Followers 115
Posts 7011
Boards Moderated 0
Alias Born 03/01/2011

Re: kingsransome post# 832

Friday, 06/21/2019 7:06:04 AM

Friday, June 21, 2019 7:06:04 AM

Post# of 2139
ContraVir Pharmaceuticals Inc. (CTRV) said it received positive feedback from the U.S. Food and Drug Administration related to CRV431, a potential liver disease drug.
Shares rose 21% to $5.21 after hours.
The FDA "provided positive feedback on ContraVir's existing preclinical data of and supports the study design" for a study of CRV431 in non-alcoholic steatohepatitis.
Earlier this month,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News